MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

  • STATUS
    Recruiting
  • End date
    Oct 1, 2030
  • participants needed
    540
  • sponsor
    Swiss Go Trial Group
Updated on 19 September 2021
cancer chemotherapy
ovarian cancer
letrozole
platinum-based chemotherapy
peritoneal cancer
tumor debulking
ovarian epithelial carcinoma
cancer of the ovary

Summary

The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.

The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).

Description

Femara (letrozole) is an extensively investigated, marketed aromatase inhibitor (AI) widely used as treatment in the maintenance phase of estrogen-receptor (ER) positive breast cancer, as it inhibit the synthesis of estrogens. Estrogen is a well known driver of cancer growth in ER-positive tumors and a high percentage of the epithelial ovarian cancers express ER as well. Of which low grade ovarian cancers demonstrates the highest level of expression, supporting our strategy of a sub-group analysis (LOGOS). Therefore, letrozole in this study be investigated prospectively and evaluated as maintenance therapy after standard surgical and chemotherapy treatment in comparison to placebo (which is the current standard maintenance treatment) in subjects with primary, ER-positive low or high grade serous or endometrioid epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) of FIGO Stage II-IV, whose cancer has not progressed by the end of the platinum-based chemotherapy.

The objectives are to evaluate the letrozole maintenance treatment compared to placebo in terms of

  • progression-free survival (PFS; primary endpoint)
  • overall survival (OS)
  • quality-adjusted progression free survival (QAPFS)
  • time to first subsequent treatment (TFST)
  • quality-adjusted time without symptoms of toxicity (Q-TWiST)
  • health related quality of life (QoL) assessed by EQ-5D-5L, FACT-ES and FACT-O questionnaires

Methods: 540 for this study eligible subjects are 1:1 allocated in this randomized, controlled, double-blinded, multi-centre study to either the test (letrozole) or control (placebo) group. The maximum maintenance treatment duration is 5 years or until symptoms of toxicity or progression of underlying disease.

Health and health-related quality of life will continuously be assessed at study entry and during routine recalls which are scheduled every 12 weeks for the first 2 years, followed by every 24 weeks for the next 3 years. Procedures performed to assess the participants' health are the same as are performed during the regular routine ovarian cancer follow-up visits: blood tests, physical as well as gynaecological examinations and may include imaging. In addition, the participants are asked to complete during the study quality of life (QoL) specific questionnaires and wear an activity tracker for one week just before the scheduled visits. These assessments will be used for the evaluation of letrozole's efficacy and burden in comparison to the standard maintenance treatment. Survival follow-up data after the mainentance treatment duration of 5 years (study end) are obtained for up to another 7 years.

Details
Condition Peritoneal Neoplasm, Abdominal Neoplasm, Fallopian Tube Cancer, Neoplasm of unspecified nature of digestive system, Abdominal Cancer, Ovarian Neoplasm Epithelial, Digestive System Neoplasms, High Grade Serous Ovarian Carcinoma, High and Low Grade Ovarian Serous and Endometrioid Carcinoma, Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma, Low-grade Serous Ovarian Carcinoma (LGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC)
Treatment Placebo, Letrozole 2.5mg
Clinical Study IdentifierNCT04111978
SponsorSwiss Go Trial Group
Last Modified on19 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must be 18 years of age
Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer
Willing and able to attend the visits and to understand all study-related procedures
(Interval-) debulking performed ECOG-Performance Status 0-2
Signed informed consents (ICF-1; ICF-2)
Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available
Positivity ( 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial)
At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)
Negative serum pregnancy test in women of childbearing potential who will get/have gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting

Exclusion Criteria

Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol
Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting)
Pregnant or lactating women
Any other malignancy within the last 5 years which has impact on the prognosis of the patient
< 4 cycles of chemotherapy in total
Contraindications to endocrine therapy
Inability or unwillingness to swallow tablets
Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note